Monkeys Develop Protective Antibodies to SARS-CoV-2

A small study of macaques finds they don’t develop a coronavirus infection the second time they are exposed, supporting the idea of using plasma from recovered patients as a treatment for COVID-19.

Written byKatarina Zimmer
| 5 min read
coronavirus covid-19 sars-cov-2 antibodies plasma therapy b cells monkey macaques

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

ABOVE: © ISTOCK.COM, SELVANEGRA

Whether people develop immunity to SARS-CoV-2 after being infected once is a pressing question for policymakers, public health professionals, and everyone affected by the spreading COVID-19 pandemic. It’s of particular interest to several research groups and companies currently developing plasma therapies, whereby antibody-containing blood plasma is extracted from recovered patients and administered to patients with severe cases to help them fight off the infection.

Now, a study in monkeys provides some clues. Three rhesus macaques did not develop a second infection after recovering from a first exposure to the coronavirus and being reexposed to SARS-CoV-2, suggesting that primates are capable of developing at least some short-term immunity to the pathogen. The research, posted as a preprint to bioRxiv March 14, has yet to undergo peer review. To the authors, the results indicate that reports of some COVID-19 survivors being “re-infected” a second time can be explained ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • katya katarina zimmer

    After a year teaching an algorithm to differentiate between the echolocation calls of different bat species, Katarina decided she was simply too greedy to focus on one field of science and wanted to write about all of them. Following an internship with The Scientist in 2017, she’s been happily freelancing for a number of publications, covering everything from climate change to oncology. Katarina is a news correspondent for The Scientist and contributes occasional features to the magazine. Find her on Twitter @katarinazimmer and read her work on her website.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies